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Abstract: Breast cancer is becoming one of the main lethal carcinomas in the recent era, and its
occurrence rate is increasing day by day. There are different breast cancer biomarkers, and their over-
expression takes place in the metastasis of cancer cells. The most prevalent breast cancer biomarker is
the human epidermal growth factor receptor2 (HER2). As this biomarker is overexpressed in malig-
nant breast tissues, it has become the main focus in targeted therapies to fight breast cancer. There is a
cascade of mechanisms involved in metastasis and cell proliferation in cancer cells. Nanotechnology
has become extremely advanced in targeting and imaging cancerous cells. Quantum dots (QDs)
are semiconductor NPs, and they are used for bioimaging, biolabeling, and biosensing. They are
synthesized by different approaches such as top-down, bottom-up, and synthetic methods. Fully
human monoclonal antibodies synthesized using transgenic mice having human immunoglobulin are
used to target malignant cells. For the HER2 receptor, herceptin® (trastuzumab) is the most specific
antibody (Ab), and it is conjugated with QDs by using different types of coupling mechanisms. This
quantum dot monoclonal antibody (QD-mAb) conjugate is localized by injecting it into the blood
vessel. After the injection, it goes through a series of steps to reach the intracellular space, and
bioimaging of specifically the HER2 receptor occurs, where apoptosis of the cancer cells takes place
either by the liberation of Ab or the free radicals.
Keywords: breast cancer; HER2 receptor; quantum dots; monoclonal antibodies; quantum dot–
antibody conjugate
1. Introduction
Cancer is the foremost difficulty of the century, and it has a tremendous impact
on the social, mental, and physical lives of human beings [1–3]. There is almost a 5%
increase in cancer occurrence in developing countries, but this rate is around 1–2% in
developed countries [1,4]. Among various types, breast cancer is the most prevalent
and the second most deadly type of cancer. Mostly, females of 45 to 55 years of age are
affected by it [5–11]. The transmembrane tyrosine kinase receptor family is termed the
human epidermal growth factor receptor (HER family), which is comprised of four types
of proteins (HER1–HER4) [12]. In around 20–30% of breast cancer patients, the human
epidermal growth factor receptor2 (HER2) receptor is overexpressed. HER2 overexpression
leads to a higher relapse rate, more violent disease, and shorter endurance [13,14]. As the
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overexpression of HER2 occurs in breast cancer, it is the major focus of targeting anticancer
therapies [15]. This receptor family is responsible for transmembrane signaling in which
cell-cell and cell–stroma communication occurs by signal transduction. Radiotherapy is
the major treatment protocol in about 50% of cancer patients [16–21].
Nanomedicine is the presentation of technology in the medical field, and lately, it has
contributed to the diagnosis and treatment of a variety of diseases (i.e., cancers) [22–33]. It
is quite possible to deliver the drug to a specific target, which is also known as vectorization.
Nanomedicine is used to deliver submicron-sized particles to the target systems for various
theranostic purposes [28,34–42]. Several nanoparticles (NPs) and nanotechnology-based
approaches have been lately introduced for fighting cancer [22,23,27,28,43]. Thanks to
unique optical properties, wide excitation spectra, and a very narrow symmetrical intense
distribution, it has become possible to apply semiconductor quantum dots (QDs) as a
versatile material system with high potential for biomedical applications [44–46]. Semicon-
ductor QDs are a novel session of fluorescent constituents. They are used for bioimaging,
biolabeling, and biosensing [47]. QDs are more significant than traditional fluorophores.
They have higher brightness, fluorescence emission tunability, and less photobleaching.
The excitation of multicolored QDs can occur by a single light source and contains broad
absorption and narrow emission spectra. The mentioned QDs seem to be the supreme
choice for scanning the cell surface receptors. The surface of QDs must be altered by using
different biological molecules to make them excellent fluorescent probes [47].
Monoclonal antibodies (mAb) are antigen-specific proteins that bind to a specific
ligand [48]. In immunotherapy, monoclonal antibodies (mAb) are bound specifically to
antigen cells for cell recognition and selective binding. Monoclonal antibodies have diverse
applications in the field of cancer therapy, i.e., for diagnosis and treatment. They are
also used in autoimmune diseases for immunosuppression [49]. Trastuzumab is the HER2
receptor-specific antibody (Ab), and after binding to the extracellular domain of HER2, with
high specificity, it hinders the proliferation of cancer cells that overexpress HER2 [50]. In
QDs antibodies, conjugate antibodies get attached to the surface of inorganic fluorophores
through different linkage mechanisms and are used in fluoroimmunoassay [51,52]. Mono-
clonal antibodies are conjugated with quantum dots by different mechanisms, e.g., either
through direct crosslinking or indirect crosslinking. Direct crosslinking occurs when the
carboxylic or amino surface groups of QDs are linked to the groups of sulfhydryl or amino
on mAbs. In the case of indirect conjugation, there will be the coating of streptavidin on
the QDs surface, which gets linked with biotinylated mAbs. Both processes have disadvan-
tages, as the surface functionalization of QDs with unadventurous antibodies by indirect
conjugation will help develop giant-sized ligands. These conjugates have inadequate
accuracy in detecting the intracellular target. Direct conjugation will result in random
mAb orientation and hinder activity. Bioconjugation can also cause denaturation of the Ab
molecules [53].
This review summarizes the mechanism of HER2 receptor involvement in breast can-
cer metastasis. After describing the mechanism of the HER2 receptor, there is a discussion
of the preparation methods of QDs and monoclonal antibodies. In the next phase of this
review article, there is a brief description of different conjugation approaches used to
attach the QDs to the monoclonal antibody (mAb) surface. In the next step, localization
of the HER2 receptor by using QDs–monoclonal Ab (QD-mAb) conjugates and the effect
produced in response to this targeting has been described. Different in-vitro methods of
characterization have also been discussed.
2. HER2 Receptor Mechanism
The monomers of HER receptors go through dimerization and transphosphorylation
of their intracellular domains when a ligand binds to their surface. As there is no direct
activating ligand of HER2, HER1 and HER3 form heterodimers with it for its activation, or
it is activated constitutively. This homo- and the heterodimerization process takes place in
the cytoplasm of the cell and leads to the autophosphorylation of tyrosine residue (Figure 1)
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and results in cell angiogenesis, differentiation, proliferation, survival, and invasion by
the activation of signaling pathways, e.g., phosphatidylinositol-4,5-bisphosphate 3 kinases
(PI3Ks), mitogen-activated protein kinases (MAPKs), protein kinase C (PKC), etc. [54].
HER2 occurs in an exposed conformation that makes it an excellent dimerization partner
for heterodimerization with other family members, and it causes more potent signals
than homodimers. When the similar monomers bind together, e.g., HER2–HER2, it is
known as homodimerization, and the association of dissimilar monomers such as HER2–
HER3, with the help of ligands or other linking agents, is called heterodimerization. The
mechanism of conformations of homo- and heterodimers of HER2 is ambiguous, and the
way in which these conformations are linked to the dimerization affinities is as of yet
undefined. The members of the EGFR group contain a ligand-binding site that allows their
mutual linkage. HER3, HER4, and EGFR have a functional ligand-binding site, but HER2
endures a sealed ligand-binding site, and it cannot bind to EGF-like ligands. In the case of
homodimerization, as there is no ligand involved, hence the homodimer remains inactive.
Interestingly, new crystal structures of Drosophila EGFR (dEGFR) ectoderms are exposed
as having asymmetric dimers that contain a single fully shaped ligand-binding site, and
the other one is fully or partially closed with one or two ligand-bound subunits. The
heterodimers were stable after ligand binding to HER3 or EGFR subunits. After removing
the single bound ligand from the HER2 heterodimer, a considerable gap formed in the
interface of the dimer.




Figure 1. Homo and heterodimerization mechanism. Different transmembrane signals are activated 
upon homo and heterodimerization, i.e., PI3K/AKT, Raf/MAPK, and PKC pathways, leading to nu-
clear transcription and modulating the genes associated with cell survivability, proliferation, and 
cell cycle progression. Here, EGFR, epidermal growth factor receptor; HER, human epidermal 
growth factor receptor; PLC, phospholipase C; PKC, protein kinase C; PI3K phosphatidylinositol 3- 
kinase; PTEN, phosphatase and tensin homolog; NF𝜅B, nuclear factor 𝜅B; mTOR, mammalian target 
of rapamycin; MAPK, mitogen-activated protein kinase; MAPKK, MAPK kinase, adapted from ref 
[54,55]. 
3. Methods of Synthesis of QDs 
Different methods are used to prepare QDs, i.e., the top–down method (Table 1), bot-
tom–up method (Table 2), and different synthetic processes. The bulk semiconductor ma-
terial is used as a precursor. A brief detail of each method is as below. 
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transcription and modulating the genes associated with cell survivability, proliferation, and cell cycle
progression. Here, EGFR, epidermal growth factor receptor; HER, human epidermal growth factor
receptor; PLC, phospholipase C; PKC, protein kinase C; PI3K phosphatidylinositol 3- kinase; PTEN,
phosphatase and tensin homolog; NFκB, nuclear factor κB; mTOR, mammalian target of rapamycin;
MAPK, mitogen-activated protein kinase; MAPKK, MAPK kinase, adapted from ref [54,55].
In the same way, an imitation of the HER2 homodimer indicated the feeble homod-
imerization of HER2 (Figure 1) [55]. The most potent stimulator of downstream pathways
is a HER2–HER3 heterodimer. For example, PI3K/Akt is the chief regulator of cell growth,
and endurance is activated by this heterodimer [56]. HER2 can also be activated by interac-
tions with other membrane receptors proteins, such as insulin-like growth factor receptor 1
(IGFR-1) [57].
3. Methods of Synthesis of QDs
Different methods are used to prepare QDs, i.e., the top–down method (Table 1),
bottom–up method (Table 2), and different synthetic processes. The bulk semiconductor
material is used as a precursor. A brief detail of each method is as below.
Table 1. The synthesis of ODs using electron beam lithography and focused ion beam (FIB) techniques, as well as an etching
technique such as the top–down approaches.
Top-Down Approach
Method Procedure Advantages Particle Size (nm) Ref
Electron beam
lithography
Beam of electron strikes with
electron-sensitive film
A high degree of
flexibility ≈30 [58]
Focused ion beam (FIB)
techniques
FIB functioned at high or low beam currents





Following the trapping of reactive gas species
in an etching system, the formed plasma
breaks down the gas molecules into more
reactive fragments with the assistance of a
controlled radiofrequency voltage
Close-packed
arrays formed 40 [58,60]





Precipitation technique using one or more solvents. Different
process parameters are carefully controlled, and QDs of specific
size and shape are prepared by a controlling ratio of cationic and
anionic species, temperature, and double-layer thickness. Bhand
et al. synthesized CdTe QDs using the wet-chemical method and
employed characterization techniques to investigate their optical,
compositional, and morphological properties. The resulting QDs
were in size range of 2.5–4 nm from the absorption peak position.
[61]
Physical vapor deposition (PVD)
Condensation is the phenomenon involved in this case. The most
commonly used PVD technique is sputtering. In PVD, a solid or
liquid source is used to vaporize the material and transported to a
vacuum, and then condensation occurs. Melvin et al. synthesized
CdSe/CdTe colloidal QDs by a physical vapor deposition method.
The PVD method has previously been used to generate niobium
oxide (Nb2O5), CdSe/CdTeQDs, and other nanocrystals.
[58]
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3.1. Using Ultrasonic or Microwave Irradiation
QDs of 1–5 nm size are prepared by passing microwave or ultrasonic radiation from
the composition of reactants in water [62]. These aural cavitations create a restricted
hotspot by adiabatic compression inside a gas crumpling bubble and lead to the formation
of QDs. Zhu et al. formulated 3 nm ZnSe NPs by passing zinc acetate solution in selenourea
solution in an argon atmosphere, where the temperature was increased to produce the
desired QDs. This process produces QDs with remarkable water-solubility, low toxicity,
stability, good reproducibility, and biological compatibility [63].
3.2. Hydrothermal Synthesis
Hydrothermal synthesis involves pressure and temperature-controlled crystallization
of inorganic salts in water to produce the quantum dots. The QDs prepared by this method
give high quantum yield and excellent photostability. This approach is more convenient,
efficient, and time-saving. Yang et al. synthesized the high-quality cysteamine-stabilized
CdTe QDs using a hydrothermal method [64].
3.3. Solvothermal Synthesis
The solvothermal technique is similar to the hydrothermal approach, except that the
precursor or reaction solution is not water in this case [65]. Du et al. fabricated CuInSe2
QDs with a diameter below the excitation Bohr radius. The preparation was directed
in oleylamine without the presence of organometallic precursors [66]. The formation of
CdSe/CdS/ZnS core-shell–shell QDs by the solvothermal method (Figure 2) includes a
series of steps. A three-necked flask was weighed down by chemicals such as 0.901 g of
oleic acid, 0.103 g of CdO, and 20 mL of tri-n-octylamine. The oxygen and water of the
mixture were eliminated by degassing it under vacuum at 150 ◦C for one hour. Under a N2
environment, the flask was heated to 300◦C by the use of a heating mantle, and after that,
0.2 mL of TOP-Se (1 M, Tri-n-octylphosphine base) solution was introduced into the flask at
300 ◦C. The resulting mixture was shaken for 90 s, and then, 0.1 mL of 1-dodecanethiol and
3 mL of tri-n-octylamine were injected gradually into the flask at the speed of 0.5 mL/min
and kept at 300 ◦C for 40 min. For the formation of the ZnS shell, 8 mL of Zn Oleate
solution was introduced above 8 min in the flask with CdSe/CdS core-shell QDs at 100 ◦C.
After that, 0.56 mL of 1-dodecanethiol and 3 mL of tri-n-octylamine were injected dropwise
to the flask at the speed of 0.5 mL/minute and kept for 30 min at 100 ◦C. The solution was
examined with the help of ethanol to form CdSe/CdS/ZnS core-shell–shell QDs [67].
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Figure 2. The f rmation of CdSe/CdS/ZnS core-shell–shell QDs by the solvothermal method. The
chemicals used were TOP-Se, dodecanthol, and Zn oleate in a three-necked flask. The specific
temperature and vacuum were applied to form these double-shell QDs, adapted from ref [67].
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3.4. Microorganism Biotemplate
The bottom-up approach has been used to synthesize and design particles of a high
surface area, having compelling applications in nanotechnology using the biotemplate
of microbial origin. Microbial biotemplates have a precise structure and size with high
growth and multiplication rates. The combinatorial phage display is used to select the
genetically engineered virus that can locate specific surfaces on semiconductors [68].
3.5. Electrochemical Assembly
Electrochemical techniques are used to generate self-assembled QDs. A chemical
reaction occurs at the junction of electrolyte and metal ions to create a template that leads
to the assembly of NPs, i.e., QDs, on the metal surface. Bandyopadhyay et al. studied
two electrochemical self-assembly procedures to generate extremely well-ordered quasi-
periodic arrays of CdS QDs. The Raman spectra of these self-assembled arrays of Cds QDs
were also provided. The QDs prepared by this method show improved defect density,
luminescence properties, and crystal quality [69]. Figure 3 shows the synthesis methods of
QDs, i.e., the top-down approach, bottom-up approach, and other synthetic techniques.
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4. Synthesis of Monoclonal Antibodies
The traditional hybridoma ap roach for Ab synthesis is comparatively difficult be-
cause it is quite a task to maintain human hybridomas and immortalized cell lines [70].
Now, the screeni g of Ab libraries is possible y incorporating Ab fragments i filamentous
bacteriophages. Similarly, a single fragment (Fab or Fc) is introduced into bacteria to
produce monoclonal antibodies [71,72]. Fully human mAb formation acts as a substitute
to reengineer murine mAb having a source of low im unogenic antibodies. Phage dis-
play technique or transgenic mice are used to form most Ab drugs, but there is no clear
difference between them. New human antibodies are prepared mainly by the use of the
advanced phage display technique [73]. Human monoclonal antibodies (mAb) can also be
prepared by using transgenic mice having human immunoglobulins. The immunization
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of transgenic mice generates a human Ab response that can form hybridomas to produce
human antibodies (Figure 4). The first fully human mAb was Humira®, which was in-
tended to treat rheumatoid arthritis [74]. The genetically modified mice and phage display
library are the two well-tolerated techniques for the formation of fully human monoclonal
antibodies (mAb) [75]. Trastuzumab is a humanized mAb (recombinant) that can attach
to the extracellular part of the HER2-tyrosine kinase receptor. In metastatic breast cancer
cells, HER2 is overexpressed, which is the best target for trastuzumab. It was approved
by Food and Drug Administration (FDA) in 1998 [76,77]. It acts by (i) HER2 receptor
internalization and degradation, (ii) Ab-dependent cellular toxicity, and (iii) MAPK and
PI3K/Akt interference [78].
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(population of cells from a multicellular organism due to mutation) to produce hybridoma cells 
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Figure 4. Human antibodies ynthesis. A XenoMou e (transgenic mous ca able of producing
human antibodies) was injected with antigen. β-cells are isolated an fused with immortalized cells
(population of cells from a multicellular organism due to mutation) to produce hybridoma cells
which, after purification, yield fully human antibodies, adapted from ref [75].
5. Polymer Coatings and Receptor Localization
QDs used for diagnostic purposes are sually prepared in an or i i t with
high temperatures and protected by hydrophobic capping molecules such as trioctylphos-
phine oxide (TOPO). However, th QDs should be hy rophilic or water-soluble for most
biological and bio-analytical purposes. To repare water-soluble CdSe/ZnS QDs, many dif-
ferent approaches (Figure 3) are used. For example, the use of hydrophilic ligand molecules
is common. These ligands include 11-mercaptoundecanoic acid (MUA), polymaleic acid n-
hexadecanol ester (PMAH), mercaptoacetic acid (MAA), polymethylmethacrylate (PMMA),
mercaptopropionic acid (MPA), dihydrolipoic acid (DHLA), mercaptosuccinic acid (MSA),
creatinine, L-arginine, etc. [79,80].
CdSe core QDs coated with ZnS are the most common type of QDs. The core exhibits
fluorescence characteristics, and the shell is for the protection and prevention of non-
radiative decay and surface flaws. Water-insoluble QDs are converted to hydrophilic dots
by applying different types of bifunctional ligand molecules—for example, phosphine,
thiol, phosphine, or mono and multidentate ligands—to improve biological properties. On
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the other hand, QDs can also be coated with hydrophilic or amphiphilic polymers (having
both a hydrophilic chain and a hydrophobic side chain) such as polyethylene glycol (PEG).
An increased number of functional groups become exposed on the surface, allowing an
easy conjugation of different targeting molecules on the surface of QDs [81].
6. QDs-Monoclonal Antibody Conjugation Mechanisms
The surface of QDs is coated with specific antibodies to form quantum dot–monoclonal
Ab (QD-mAb) conjugates. There are different crosslinking mechanisms for this conjugate
formation.
6.1. Non-Covalent Linking
Different approaches are used to conjugate QDs with antibodies non-covalently. These
methods include adsorption, direct attachment, and the streptavidin-biotin approach.
6.1.1. Adsorption
Passive adsorption is a straightforward and traditional approach to bio-conjugate
the QDs. Both hydrophilic and hydrophobic QDs can be used in this case. In the case of
hydrophobic QDs, adsorption occurs by the association between aromatic amino acids
or non-polar molecules with QDs surface coatings. In the same way, the adsorption of
hydrophilic particles occurs by the electrostatic interactions between polar molecules and
surface coatings of QDs. Proteins undergo a conformational change before attaching with
hydrophobic or non-polar particles, as proteins have external hydrophilic molecules [82–84].
This is a commonly used approach in which the bond is formed between biomolecules
having a positive charge and QDs bearing a negative charge (Figure 5). This process has
drawbacks, i.e., weak charge distribution, leading to the detachment and exchange of
molecules to another. It is also affected by external factors such as pH, temperature, and
ionic strength. Cunha et al. used this method to adsorb negatively charged QDs with lectin
to label Candida albicans [83–86].
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by the contribution of electrons of two atoms from a thiol group of biomolecules is called
a dative bond. These bonds usually have greater length and less energy than a covalent
bond.
Thiol interaction ith the QD surface is exhibited by extre ely dyna ic off-rates,
which can restrict conjugation stability over the long run. By raising the number of
interactions (i.e., multivalency), these forms of bonds can be strengthened. By motifs, the
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divalent transition of metals present on the QD surface can be realized to the metal affinity.
Unlike covalent interactions, this technique usually results in protein–QD dispersity with
no or low particle aggregation. Palomo et al. used this technique to associate QDs with cell
glycans [83,85,86].
The imidazole ring at the histidine residue binds with positively charged metal at the
QDs surface to form metal-affinity linkages between QDs and biomolecules (Figure 6a). Bio-
conjugation can be enhanced by increasing the histidine (His) amino acid of biomolecules.
Sulfhydryl groups in thiolated molecules (Figure 6b) can form a dative bond with metal for
bio-conjugation. The main disadvantage of this process is the need for thiol residues of
biomolecules [87]. Proteins [88–90], polymers [91], viruses [91], and carbohydrates [91,92]
are the molecules linked through the direct linking process [86].
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6.1.3. Streptavidin–Biotin Binding
The high-affinity linkage bet een streptavidin and biotin has been extensively used for
QDs biomolecule conjugation (Figure 7). This method is sometimes mentioned as a covalent
bond because it is the strongest non-covalent bond. As this is the near-covalent bond, it is
mostly unaffected by pH, temperature, procedure steps, and buffer salts [86,93,94]. Biotin
is called vitamin H or B7, and it is a tiny molecule. It is incorporated with biomolecules and
does not affect the characteristics of biomolecules. Biotin has a carboxylic group that allows
it to be conjugated with different molecules [84]. Streptavidin is a protein having binding
potential with biotin. It has four subunits, and each unit has a binding site to biotin. It
has less affinity with carbohydrate receptors because it is a non-glycosylated protein. The
major disadvantage of this technique is the huge size of the concluding structure.
On the other hand, there is a need to biotinylate the biomolecules for streptavidin-
biotin conjugation [84]. There is a need to functionalize the QDs surface with streptavidin so
that the biotinylated biomolecule can be attached to it [95]. Antibodies, proteins, peptides,
and nucleotides use this approach for bio-conjugation. Ghimire et al. produced QDs-linked
polymers through the streptavidin–biotin-binding [96,97].
6.2. Covalent Linking
The QDs and antibodies can be covalently linked by three mechanisms, i.e., (i) zero-
length coupling, (ii) homobifunctional coupling, and (iii) heterobifunctional coupling.
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6.2.1. Zero-Length Coupling
As linking agents in the zero-length coupling, Carbodiimides, by shaping amide bonds,
facilitated the reaction of carboxylic acid groups with amine groups. In this case, amino
acids are covalently attached through carbodiimide linkage (Figure 8a). Carbodiimides can
be either hydrophilic or hydrophobic in nature. The reaction between QDs and antibodies
occurs in an aqueous buffer solution, and it requires the use of water-soluble carbodiimide,
i.e., EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride). Typically, a
preservative i pplied besid EDC. The most commonly used pr servative or additive with
EDC is NHS N-hydroxysuccinimide or sulfo-NHS [82,98]. In this case, the biomo ecules
get polymerized with many amine and carboxylic groups. This is the major disadvantage
of this process. The purification of biomolecules can avoid this polymerization but leads
to the denaturation of the biomolecule. To avoid this drawback, the surface of QDs is
coated with carboxylic acid and treated with EDC/sulfo NHS [84,94]. Different kinds of
biomolecules and NPs use this technique. Yun et al. used EDC/NHS agents to conjugate
DNMT1 polyclonal Ab (PcAb) to CdSe/ZnS QDs [86].
6.2.2. Homobifunctional-Coupling
Homobifunctional coupling agents are used to covalently link the two amino groups
on the QDs surface and biomolecules. In this case, glutaraldehyde is used to couple
biomolecules having amine moieties with aminated QDs. Glutaraldehyde contains two
aldehyde groups. These coupling agents have two indistinguishable amine-reactive loca-
tions: aldehydes or NHS esters (Figure 8b). This can proceed in either one or two steps.
QDs, biomolecules, and coupling agents are mixed simultaneously in a one-step process,
so there are chances of amine linkage between two QDs or between QDs or biomolecules.
This is the major drawback of this process. In a two-step process, QDs and coupling agents
are mixed in the first step; then, there will be a purification step to eliminate the coupling
agent. After that, a biomolecule is introduced, and a final bio-conjugate is formed. Zhong
et al. used this technique to bind QDs with anti-Escherichia coli antibodies by using glu-
taraldehyde as a coupling agent. Hydrolysis is the major disadvantage of this process [86].
Different peptides and proteins [99], receptor ligands [100], nucleic acids [101], lectins [102],
and antibodies [103] can be conjugated by using this technique.
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6.2.3. Heterobifunctional Coupling
A heterobifunctional coupling agent has two reactive groups, one amine and the other
sulfhydryl, and they are used to covalently attach a thiol and an amine group (Figure 8c).
Activated esters such as NHS ester are used when there is a reaction with an mine. On
the other hand, reaction with the sulfhydryl group occurs in the presence of either maleic
anhydrid or compounds having disulfide bonds [86]. On the thiol-reactive side, mostly
maleic existing anhydride derivatives ar reacted by the sulfhydryl compounds to form
a thioether. The most often used heterobifunctional coupling agent to link biomolecules
to the QDs surface is succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate
(SMCC). This reaction process includes two steps: firstly, the addition of the amine-reactive
group (step 1), and then the addition of the thiol-reactive group (step 2). This technique
is used to conjugate proteins [104] and antibodies. Brunetti et al. used this technique to
link commercial QDs-NH2 with tetra-branched peptides (NT4 peptides) used as cancer
therapeutic agents [105].
7. HER2 Receptor Targeting by QD-mAB Conjugate
There are six steps involved in the site-specific transport of QD-mAb conjugate
(Figure 9) from tumor vessels to the perinuclear area of the cell. These steps include
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(i) circulation in the tumor vessel, (ii) extravasation, (iii) drive in the extracellular space,
(iv) attach to HER2 receptor located on the cell membrane, (v) endocytosis to move inside
of the cell to the perinuclear region, and (vi) the perinuclear region. During the movement
through the different sites, the speed of the conjugate was different in different locations.
The movement was stop-and-go based, i.e., remaining in the highly restricted region and
then moving abruptly. Protein-protein interactions and three-dimensional structures con-
trolled this movement. The motive power generated by blood circulation was used to
promote the movement of the conjugate. The conjugate entered into the circulation, and
then it was extravagated to the vascular space from interstitial space. After the extracellular
movement, the QD-mAb conjugate was attached to the HER2 receptor. After binding to the
receptor, it was internalized by endocytosis and reached the perinuclear area. Very little is
known about the behavior of NPs inside biological systems. There is a rough estimation of
the steps, including blood circulation, cellular localization and movement in the cytoplasm,
and reaching the final destination in the target cell or molecule [106,107]. Targeted delivery
and uptake feed the cell’s tendency to identify and internalize the QDs conjugated with spe-
cific macromolecules (QDs-mAb conjugate) and transport them to intracellular structures
such as the nucleus. Advanced techniques such as electroporation enclose the QDs with a
nuclear localization sequence and then translocation into the nucleus [108,109]. Antibodies
(Trastuzumab in case of HER2) urge the QDs to bind specifically to the HER2 receptor
on cancer cell lines (SKBR3 cell lines for HER2 receptor). After binding, QDs leads to
programmed cell death and apoptosis by forming reactive oxygen species (ROS) generated
by UV or infrared energy emissions. On the other hand, free Ab (Herceptin/Trastuzumab)
is also released to cause apoptosis [110]. There are different QDs breast-targeted deliveries
discussed in Table 3.
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Figure 9. HER2-receptor targeting by QD-mAb conjugate. After injecting into the tumor vessel, the
QD-mAb conjugate enters into the endothelial cell through extravasation; then, in a rotating manner,
it causes extracellular movements, after which it becomes attached to the HER2 receptor. After that,
internalization through vesicle formation occurs, and intracellular binding occurs in the final step,
adapted from ref [111].
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Table 3. QDs-based breast cancer targeted (HER2 receptor-targeted) deliveries.
Targeted Deliveries Details Ref
Near-IR QDs-loaded micelles
The high absorption of the near-IR
QDs-loaded micelles by HER2
receptor-overexpressing carcinoma cells,
which are distributed fast in-vivo.
[112]
Inorganic nanoparticles with a
core/shell configuration.
Metals (e.g., iron oxide, gold, and QDs)
or organic fluorescent dyes
encapsulated in silica form the core,
while metals or organic polymers form
the shell
The HER2 receptor is exploited to target
magnetic NPs in breast cancer tissue for
imaging and diagnostic purposes.
[113]
Biomarker-targeted fluorescent probes
Breast cancer cells and associated animal
models are scanned using fluorescent
probes. Fluorescent probes are superior
to other diagnostic methods in terms of
high selectivity, sensitivity, specificity,
signal intensity, and early diagnosis.
[114]
QDS-based inorganic NPs for HER2
receptor targeting
The application of targeted multimodal
NPs as vectors in therapeutic purposes,
sources of signals in diagnostic purposes,
and monitor endogenous response
simultaneously.
[115]
QDs in breast cancer therapy
As a result of their ultra-sensitivity,
bio-conjugated QDs were used to detect
metastasis, especially micro-metastasis.
QDs may also be employed to track
circulating tumor cells or even circulating
stem cells, which are essential prognosis
factors and sources of cancer recurrence.
[116]
8. In-Vitro Characterization of QDS
Photoluminescence spectroscopy is used for the characterization of the optical proper-
ties of QDs. Deposited QDs structures were analyzed by using photomodulated reflectance
spectroscopy. This approach gives a similar energy resolution profile to that of photolumi-
nescence. The band structure, specifically the wetting layer, can be analyzed by inter-band
optical transitions, and a broader range of critical points emphasize the ground state operat-
ing at low temperature comparatively [108]. The QDs’ size is the crucial factor determining
optical characteristics, and size plays a vital role in regulating the purity and spectral
positions of photoluminescence. Dynamic light scattering (DLS), transmission electron mi-
croscope (TEM) and transmission electron microscope (TEM) study, and scanning electron
microscopic (SEM) analysis are the approaches used to calculate the size of QDs. Scientists
have calculated the size and arrangement of CdZnSe/ZnBeSe by using Raman scattering
spectroscopies in combination with photoluminescence [117]. Field flow fractionation was
also used to characterize hydrophilic QDs [118]. The size of the QDs prepared led to epitax-
ially different techniques being employed such as TEM analysis, atomic force microscopy
(AFM), and scanning tunneling microscopy (STM) [119]. STM was used to calculate the
quantum size effect and shapes of InAs and InGaAs QDs [120]. Surface chemistry of QDs is
characterized by using Rutherford backscattering, X-ray photoelectron spectroscopy (XPS)
study, and nuclear magnetic resonance spectroscopy (NMR) imaging. An extremely robust
ultracentrifugation technique was used to characterize the size distribution and surface
chemistry of QDs [121].
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8.1. In-Vitro Characterization of QD-mAb Conjugate
High-resolution transmission electron microscopy (HRTEM) is used to analyze the
shape and size of the QDs-mAb conjugate. Highly differentiated cores of QDs can be
analyzed after conjugation as large biological molecules are attached to the surface, so there
would be enhanced spacing between each QD [122]. Spectrum analysis of QDs with and
without the conjugation was analyzed by spectrum analysis to confirm the conjugation
process. The appearance of certain peaks at certain wavelengths confirmed the conjugation
of QDs surface with antibodies. UV-VIS spectra also show a positive conjugation process
as the absorption of the peak lies in the UV range [123,124]. Zeta potential is another
analysis that confirms that antibodies occupy the surface. In this case, when a negatively
charged ligand binds to the QDs surface, there will be a negative zeta potential. When an
Ab binds to the surface, there will be a positive zeta potential value because of the amino
groups of the Ab [125–127]. Different stretching and bending peaks were analyzed by
FTIR analysis to ensure the efficacy of coupling reactions [128]. Morphology, size, binding
capability, and molecular weight were determined by atomic force microscopy (AFM),
while discontinuous sodium dodecyl sulfate agarose gel electrophoresis (SDS-AGE) was
applied to determine molecular biology.
In contrast to the contact mode of AFM, the tapping mode has a less damaging effect
on the surface, and it is a very adaptable technique to analyze the surface nanostructure. It
is used to study the qualitative and quantitative properties such as the height, angstrom
level resolution, shape, and association of surface-adsorbed NPs [129,130]. Here, the
heights are measured by topography AFM, while the phase AFM is used to study the
morphology of conjugates. Nucleic acid migration, separation of high molecular weight
species, and electrophoretic mobility shift assays are performed using AGE [130]. Using
this technique and electrophoresis, different biomolecules such as nucleic acids, peptides,
and oligonucleotide-modified QDs are analyzed [131]. SDS-AGE molecular weights can
elucidate the relative sizes and migration patterns of the QD-mAb conjugate. The size and
shape results from AFM can be validated by SDS-AGE [132]. A literature review of HER2
receptor targeting by QDs-mAb conjugates is briefly discussed in the next section.
8.2. HER2 Receptor Targeting by QDs-mAb Conjugates
Tada et al. used a single-particle quantum dot linked with cancer-targeting Ab in the
tumors of living mice using a dorsal skinfold chamber and a very fast confocal microscope
with a highly sensitive camera. QDs conjugated with the monoclonal anti-HER2 Ab were
inoculated into the mice having HER2-overexpressing breast cancer to examine the molecu-
lar methods of its mechanistic distribution to the tumor. By using a dorsal skinfold chamber,
the drive of single complexes of the QDs-Ab could be evidently detected at 30 frames per
second inside the tumor. Six procedures of delivery were examined efficaciously such as (i)
firstly in the blood vessel or circulation region, (ii) extravasation, (iii) in the extracellular
environment, (iv) on the cell membrane for binding to HER2, (v) movement from the cell
membrane to the perinuclear section, and (vi) in the perinuclear region. The photo anal-
ysis of the movement processes of single particles in-vivo gives evidence on therapeutic
nanoparticles conjugated to the Ab, which can enhance therapeutic efficacy [111]. Seung-
Jin et al. immobilized a classic monoclonal Ab, Herceptin, on the surface of CdSe/ZnS
core-shell QDs to increase their particular connections with breast cancer cells (SK-BR3).
Dynamic light scattering was used to detect the average size of the core-shell QDs, i.e.,
28 nm. This size showed an increase up to 86 nm after the immobilization of Herceptin. The
in-vitro cell culture testing indicated that the keratin-forming cancer cells (KB) multiplied
significantly in the existence of Herceptin-linked QDs (QDs-Her, 5 nmol/mL).
In the same way, most of the breast cancer cells (SK-BR3) were found dead. The inter-
face of QDs-Her with SK-BR3 cells was examined, by confocal laser scanning microscopy, to
elucidate the cell death. The QDs-Her was linked particularly to the membrane of SK-BR3
cells, and the membrane became saturated after 6 h of incubation. This indicates that the
specific binding of Herceptin to the HER2 receptor of the SK-BR3 membrane completely
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inhibited the growth signal of breast cancer and resulted in cell death [110]. Takashi-Jin
et al. used QDs conjugated antibodies that are the most significant fluorescent probes. A
simple process was used to conjugate the Ab on the surface of QDs. ProteinA was applied
as an adaptor protein to bind the Ab to the QDs for surface imaging. Numerous types
of antibodies can easily bind to the surface of QDs by non-covalent attachment between
the Fc (fragment crystallization) part of the Ab after their linkage with ProteinA. HER2 in
KPL-4 human breast cancer cells was marked by the use of anti-HER2 Ab-linked ProteinA-
QDs to indicate the usefulness of ProteinA-conjugated QDs. The multiplexed imaging
of CXCR4 (chemokine receptor) and HER2 in KPL-4 cells was carried out. The result
indicated that CXCR4 receptors co-occur with HER2 receptors in the surface membrane of
KPL-4 cells. In living cells, the multiplexed imaging of surface receptors is performed by
ProteinA-facilitated Ab conjugation to QDs [47].
Tatsiana et al. performed immunolabeling of breast and lung cancer cell lines by ultra-
small and shiny nanoprobes associated with QDs conjugated to single-domain anti-HER2
antibodies. Their efficiency was compared to traditional organic dyes (Alexa Fluor 568 and
Alexa Fluor 488)-labeled anti-HER2 monoclonal antibodies. The single-domain antibodies
conjugated to QDs (sdAbs-QDs) attained greater staining in a board of lung cancer cell lines
having distinct HER2 expression. This indicates their excellent perspective for the progress
of more sensitive assays for the initial examination of cancer biomarkers [133]. Rizvi
et al. characterized the near-infrared-emitting QDs, and their in-vitro toxicity was proven
by using three cancer cell lines such as SK-BR3 (HER2-overexpressing), MCF7 (HER2-
underexpressing), and HepG2. Mouse anti-human anti-HER2 monoclonal Ab was linked
to the near-infrared-emitting QDs. In-vitro toxicity testing indicated the biocompatibility of
MCF7 and SK-BR3 cell lines at 60 µg/mL concentration after one hour and 24 h of exposure
using near-infrared-emitting QDs. HER2 receptors were effectively localized on SK-BR3
cells by near-infrared-emitting QDs anti-HER2 Ab bioconjugates [128].
9. Applications of QDs
QDs have multiple biodiagnostic, bioimaging, photodynamic therapy, and targeted de-
livery applications. Some of the applications of QDs are summarized in Figure 10 [134,135].
Specific receptors are targeted by QDs coated with receptor-specific moieties such as folate,
which was conjugated to the surface of QDs for receptor-specific targeting [136]. The QD–
biomolecule (e.g., folate) conjugates were noticed in mouse lymphoma after some time of
incubation. A precise targeting was observed by folate at folate receptors demonstrated by
the increase in fluorescence concentration in non-specific QDs. There will be an increased
expression of folate receptors in cancer cells, and this range is determined by folate, a
nutrient. Then, this degree of folate expression will be used to diagnose cancer, as the
overexpression is a sign of malignancy [137].
Photostable QDs are used to record images for extended periods compared to fluores-
cent dyes because they have a lower photobleaching effect. Cd containing QDs was visible
even after several days after intraocular injection using in-vivo imaging approaches [138].
For the in-vivo experiment, mice were injected with these QDs subcutaneously, and fluo-
rescence was determined in brain areas, specifically. In this case, the highest fluorescence
was noticed after three days, and it lasted for seven days. The exact position of the conju-
gates was determined at subcellular level resolution. It was observed that the QDs were
internalized into various cell types, as their internalization of QDs is considered a novel
technique in in-vivo neuroimaging studies [137]. Live cell imaging and detection can be
performed by QDs as well.
Both external and internal imaging of cells is possible. Different techniques such as
cell-mediated delivery and surface modifications are used to determine cell imaging and
internalization applications [139,140]. The QDs can be tracked into human breast cancer
cells [111]. Anti-HER2 antibodies conjugated with QDs were used to locate the NPs in
tumor cell blood vessels in mice. The whole process, including the conjugate movement in
blood vessels, then extravasation step, movement in the extracellular cellular environment,
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adhesion to HER2 receptors on the cell surface, and internalization step, was visualized.
This process is a novel technique and can track different biomolecules and comprehend
subcellular movements [137]. QDs are used to track cancer cells in-vivo in metastasis [141].
QDs coated with tumor-targeting antibodies have been developed and were injected into
mice. The in-vivo studies showed the accumulation of these conjugates into the tumoral
cells. Meanwhile, in another approach, the QDs-labeled tumoral cells were injected into
mice, and in both cases, they were tracked by multiphoton microscopy. In both cases, the
results indicated the multicolor in-vivo visualization [142].
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with QD-Ab conjugates for one h ur by Yezhelyev t al. Cell lin s were marked with five
different kinds of QDs, and it was found that the cancer biomarkers were present either on
the cell membrane or in the nucleus of the cell. Further breast cancer cell analysis confirmed
that by computing the fluorescence intensity of QDs, the extent of quantitative appearance
of cancer biomarkers could be calculated concurrently [144]. Förster resonance energy
transfer (FRET) is a very influential technique used to study biological interactions that
works through QDs [145]. There should be simplistic conjugation approaches used, and
coatings must be water-soluble to conjugate the biological molecules with QDs. Stable and
biocompatible QDs are produced to be incorporated in this technique. Immunohistochem-
istry (IHC) has been used to diagnose and predict human cancer for the last 80 years [146].
In this case, multicolored molecular profiling is not possible. Multiplexing is essential to
define the cancer stage, as it can show more than one type of biomarker simultaneously.
IHC is a semi-quantitative technique leading to inter-observer variations in results. QDs
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have played a unique role in multiplexed fluorescent labeling. It is a very informal and
convenient technique. Multiple colored QDs are excited simultaneously, and their emission
is used as an advanced photostable approach for imaging the samples [146,147]. Exclusive
physical and optical characteristics make QDs extraordinary candidates for biosensing and
bioimaging, as they can attach many biological molecules on their surface. QDs are used in
modern DNA and protein recognition methods; in recent years, a QD marked with aptamer
(a nucleic acid) was used to unmark adenosine triphosphate (ATP). Three carcinoma cell
lines, HepG2, SK-BR-3 (HER2 overexpressing), and MCF7, were used to characterize near-
infrared (NIR)-emitting QDs and determine their in-vitro toxicity (HER2 underexpressing).
A mouse’s anti-human anti-HER2 mAb was coupled to QDs that generate near-infrared
(NIR) light [128]. The safety of NIR-emitting QDs at a 60 g/mL concentration was con-
firmed by exposing cancer cells for one h and 24 h under in-vitro toxicity experiments.
QD–antiHER2–Ab bioconjugates that produce NIR light successfully targeted HER2 recep-
tors on the surface of carcinoma cells (SK-BR-3 and MCF7 cell lines) [128]. Another study
used QD immunohistochemistry (QD-IHC) to measure ki67. This study exhibited the
significance of QD-IHC to predict breast cancer by detecting HER2-positive (non-luminal).
The identification of breast cancer was conducted by looking at the expression of the
Ki67 marker in 108 breast cancer tissues (non-luminal) with HER2-positive by using both
QD-IHC and IHC. QDs-IHC to a found antigen location acts as traditional IHC. Both
techniques have a reasonable correlation of staining rates (r = 0.993). Additionally, these
methods found an excellent agreement of measurements (=0.874) of Ki67 expression (cutoff:
30%) in breast cancer. However, for the Ki67 score, the QD-IHC method demonstrated
more high-grade inter-observer agreement than traditional IHC. Ki67 expression levels
above 30% were linked to shorter disease duration (in a disease-free state), particularly in
lymph node-negative. Ki67 detection and assessment were made more accessible and more
accurate using QD-IHC imaging. The Ki67 score was shown to be an independent predictor
of survival in breast patients with HER2-positive (non-luminal) [148]. Different advantages
and disadvantages of QDs usage in breast cancer-targeted deliveries are summarized in
Table 4.
Table 4. Advantages and disadvantages of quantum dots (QDs) usage in breast cancer-targeted
deliveries.
Advantages Disadvantages Ref
Biological imaging, diagnosis, and
therapeutic applications High toxicity [149]
High photostability and no
photobleaching
In high breast cancer cell lines, QDs are
epigenetic and genotoxic carcinogens [149]
Versatility for bio-conjugation with
various biomolecules
Detection or diagnosis of cancer is limited
to superficial sites [150]
In comparison with organic
fluorophores, the QDs amplify signal
brightness up to 10–100 times more
As a result of the oxidative breakdown of
its heavy metal core, metal ions will be
released into the environment, where they
will attach to the thiol functional group of
intracellular proteins and cause the
function of subcellular organelles to be
impaired
[150]
10. Conclusions and Outlook
This review summarizes the targeting of the cancer biomarker HER2 receptor by
using quantum dot monoclonal Ab conjugate (QD-mAb). QDs can be used for nucleic
acid detection, drug treatments, real-time imaging of cancer cells, and a wide range of
other biomedical applications. QDs are considered the most advanced technique for cell
labeling and imaging. Different preparation methods of QDs have been discussed, e.g., the
top-down approach and the bottom-up approach.
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The mAb preparation from XenoMouse was performed, as the conventional tech-
niques are time consuming. Trastuzumab is the main Ab used for HER2-receptor targeting.
There are different coupling techniques to conjugate the surface of QDs with biomolecules.
The conjugation of Ab to QD helps selectively locate the tumor cells and destroy them
either by free radicals or free Ab release. HER2 receptor localization, which is the article’s
main point, is elaborated as the migration of the conjugate from the blood vessel to the in-
tracellular space. In-vitro characterization techniques of the QDs and QD-mAb conjugates
and some in-vivo studies and applications of QD Ab conjugate have been deliberated.
As a result of their outstanding optical properties, the use of QDs in breast research
will increase shortly. QDs-based imaging techniques have demonstrated their promis-
ing applicability in the simultaneous quantification of breast cancer biomarkers. These
biomarkers, such as HER2 receptors, are upregulated in breast tumors and can be detected
using these innovative methods even in the tumor microenvironment.
Numerous reports have already shown the successful use of QDs against breast cancer;
however, concerning their in-vivo application, caution must be taken due to the undesirable
toxicity of QDs’ components. Still, the efficient delivery of these multifunctional biomateri-
als and their conjugates is profoundly affected by their nature and the type of the studied
cells. Therefore, developing relevant safety regulations is needed for commercialization.
There are some obstacles in using QDs for breast cancer therapy, such as their relatively
large size for medical imaging, the stereospecific blockade effect, in-vivo aggregation of
QDs, and their toxic effects. Still, we firmly believe that these nanostructures are more
beneficial to nanomedicine to dismiss, and biocompatible QDs will ultimately be available
for routine clinical use in breast cancer patients.
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16. Haume, K.; Rosa, S.; Grellet, S.; Śmiałek, M.A.; Butterworth, K.T.; Solov’yov, A.V.; Prise, K.M.; Golding, J.; Mason, N.J. Gold
nanoparticles for cancer radiotherapy: A review. Cancer Nanotechnol. 2016, 7, 8. [CrossRef]
17. Delaney, G.P.; Barton, M.B. Evidence-based estimates of the demand for radiotherapy. Clin. Oncol. 2015, 27, 70–76. [CrossRef]
18. Peydayesh, M.; Raisi, M.; Kaykavousi, K.; Gharaghani, M.A.; Abdollahpour-Alitappeh, M.; Mosazade, F.; Seifalian, A.; Khatami,
M. The inhibitory effect of Tamarix hispida mediated silver nanoparticles on Cyclin D1 protein expression of human cancer cells
line. Inorg. Nano-Met. Chem. 2020, 50, 1144–1149. [CrossRef]
19. Poor, M.H.S.; Khatami, M.; Azizi, H.; Abazari, Y. Cytotoxic activity of biosynthesized Ag nanoparticles by Plantago major towards
a human breast cancer cell line. Rend. Lincei 2017, 28, 693–699. [CrossRef]
20. Sharifi, F.; Sharififar, F.; Sharifi, I.; Pournamdari, M.; Eslaminejad, T.; Khatami, M. Antioxidant, anti-proliferation and cytotoxicity
activities of Gossypium hirsutum toward standard HepG2, A549, MCF-7 and U87 cancer cell lines compared to HUVEC, 3T3
normal cells. Eur. J. Med. Plants 2017, 21, 1–10. [CrossRef]
21. Yaghoubi, S.; Karimi, M.H.; Lotfinia, M.; Gharibi, T.; Mahi-Birjand, M.; Kavi, E.; Hosseini, F.; Sineh Sepehr, K.; Khatami, M.;
Bagheri, N. Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. J. Cell. Physiol. 2020, 235,
31–64. [CrossRef] [PubMed]
22. Shakeri-Zadeh, A.; Zareyi, H.; Sheervalilou, R.; Laurent, S.; Ghaznavi, H.; Samadian, H. Gold nanoparticle-mediated bubbles in
cancer nanotechnology. J. Control. Release 2020, 330, 49–60. [CrossRef] [PubMed]
23. Sharma, A.; Saini, A.K.; Kumar, N.; Tejwan, N.; Singh, T.A.; Thakur, V.K.; Das, J. Methods of Preparation of Metal-Doped and
Hybrid Tungsten Oxide Nanoparticles for Anticancer, Antibacterial, and Biosensing Applications. Surf. Interfaces 2022, 28, 101641.
[CrossRef]
24. Irajirad, R.; Ahmadi, A.; Najafabad, B.K.; Abed, Z.; Sheervalilou, R.; Khoei, S.; Shiran, M.B.; Ghaznavi, H.; Shakeri-Zadeh, A.
Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform:
An in vivo study. Cancer Chemother. Pharmacol. 2019, 84, 1315–1321. [CrossRef]
25. Mashayekhi, S.; Rasoulpoor, S.; Shabani, S.; Esmaeilizadeh, N.; Serati-Nouri, H.; Sheervalilou, R.; Pilehvar-Soltanahmadi, Y.
Curcumin-loaded mesoporous silica nanoparticles/nanofiber composites for supporting long-term proliferation and stemness
preservation of adipose-derived stem cells. Int. J. Pharm. 2020, 587, 119656. [CrossRef] [PubMed]
26. Almanghadim, H.G.; Nourollahzadeh, Z.; Khademi, N.S.; Tezerjani, M.D.; Sehrig, F.Z.; Estelami, N.; Shirvaliloo, M.; Sheervalilou,
R.; Sargazi, S. Application of nanoparticles in cancer therapy with an emphasis on cell cycle. Cell Biol. Int. 2021, 45, 1989–1998.
[CrossRef]
27. Sheervalilou, R.; Shahraki, O.; Hasanifard, L.; Shirvaliloo, M.; Mehranfar, S.; Lotfi, H.; Pilehvar-Soltanahmadi, Y.; Bahmanpour, Z.;
Zadeh, S.S.; Nazarlou, Z. Electrochemical nano-biosensors as novel approach for the detection of lung cancer-related MicroRNAs.
Curr. Mol. Med. 2020, 20, 13–35. [CrossRef]
28. Sheervalilou, R.; Shirvaliloo, M.; Sargazi, S.; Ghaznavi, H. Recent advances in iron oxide nanoparticles for brain cancer theranostics:
From in vitro to clinical applications. Expert Opin. Drug Deliv. 2021, 18, 949–977. [CrossRef]
29. Liu, J.; Chen, Q.; Feng, L.; Liu, Z. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement.
Nano Today 2018, 21, 55–73. [CrossRef]
30. Zou, Q.; Xing, P.; Wei, L.; Liu, B. Gene2vec: Gene subsequence embedding for prediction of mammalian N6-methyladenosine
sites from mRNA. RNA 2019, 25, 205–218. [CrossRef]
31. Jiang, Q.; Jin, S.; Jiang, Y.; Liao, M.; Feng, R.; Zhang, L.; Liu, G.; Hao, J. Alzheimer’s disease variants with the genome-wide
significance are significantly enriched in immune pathways and active in immune cells. Mol. Neurobiol. 2017, 54, 594–600.
[CrossRef]
32. Zou, Y.; Wu, H.; Guo, X.; Peng, L.; Ding, Y.; Tang, J.; Guo, F. MK-FSVM-SVDD: A multiple kernel-based fuzzy SVM model for
predicting DNA-binding proteins via support vector data description. Curr. Bioinform. 2021, 16, 274–283. [CrossRef]
33. Shirvalilou, S.; Khoei, S.; Esfahani, A.J.; Kamali, M.; Shirvaliloo, M.; Sheervalilou, R.; Mirzaghavami, P. Magnetic Hyperthermia as
an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma:
A systematic review. J. Neuro-Oncol. 2021, 152, 419–428. [CrossRef] [PubMed]
34. Dai, Y.; Xu, C.; Sun, X.; Chen, X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour
microenvironment. Chem. Soc. Rev. 2017, 46, 3830–3852. [CrossRef]
J. Funct. Biomater. 2021, 12, 75 20 of 24
35. Yan, S.; Yan, J.; Liu, D.; Li, X.; Kang, Q.; You, W.; Zhang, J.; Wang, L.; Tian, Z.; Lu, W. A nano-predator of pathological MDMX
construct by clearable supramolecular gold (I)-thiol-peptide complexes achieves safe and potent anti-tumor activity. Theranostics
2021, 11, 6833. [CrossRef]
36. Reang, J.; Sharma, P.C.; Thakur, V.K.; Majeed, J. Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to
Overcome Cancer. Biomolecules 2021, 11, 1130. [CrossRef] [PubMed]
37. Cao, Y.; Alijani, H.Q.; Khatami, M.; Bagheri, F.; Iravani, S.; Sharifi, F. K-doped ZnO nanostructures: Biosynthesis and parasiticidal
application. J. Mater. Res. Technol. 2021, 15, 5445–5451. [CrossRef]
38. Zarrabi, A.; Zarepour, A.; Khosravi, A.; Alimohammadi, Z.; Thakur, V.K. Synthesis of Curcumin Loaded Smart PH-Responsive
Stealth Liposome as a Novel Nanocarrier for Cancer Treatment. Fibers 2021, 9, 19. [CrossRef]
39. Arshad, R.; Barani, M.; Rahdar, A.; Sargazi, S.; Cucchiarini, M.; Pandey, S.; Kang, M. Multi-Functionalized Nanomaterials and
Nanoparticles for Diagnosis and Treatment of Retinoblastoma. Biosensors 2021, 11, 97. [CrossRef]
40. Barani, M.; Rahdar, A.; Sargazi, S.; Amiri, M.S.; Sharma, P.K.; Bhalla, N. Nanotechnology for inflammatory bowel disease
management: Detection, imaging and treatment. Sens. Bio-Sens. Res. 2021, 32, 100417. [CrossRef]
41. Rahdar, A.; Sargazi, S.; Barani, M.; Shahraki, S.; Sabir, F.; Aboudzadeh, M.A. Lignin-stabilized doxorubicin microemulsions:
Synthesis, physical characterization, and in vitro assessments. Polymers 2021, 13, 641. [CrossRef] [PubMed]
42. Rahdar, A.; Hajinezhad, M.R.; Sargazi, S.; Zaboli, M.; Barani, M.; Baino, F.; Bilal, M.; Sanchooli, E. Biochemical, Ameliorative and
Cytotoxic Effects of Newly Synthesized Curcumin Microemulsions: Evidence from In Vitro and In Vivo Studies. Nanomaterials
2021, 11, 817. [CrossRef]
43. Norouzi, M.; Yasamineh, S.; Montazeri, M.; Dadashpour, M.; Sheervalilou, R.; Abasi, M.; Pilehvar-Soltanahmadi, Y. Recent
advances on nanomaterials-based fluorimetric approaches for microRNAs detection. Mater. Sci. Eng. C 2019, 104, 110007.
[CrossRef]
44. Akbarzadeh, A.; Aval, S.F.; Sheervalilou, R.; Fekri, L.; Zarghami, N.; Mohammadian, M. Quantum dots for biomedical delivery
applications. Rev. Cell Biol. Mol. Med. 2016, 2, 19. [CrossRef]
45. Zhou, W.; Coleman, J.J. Semiconductor quantum dots. Curr. Opin. Solid State Mater. Sci. 2016, 20, 352–360. [CrossRef]
46. Chung, S.; Revia, R.A.; Zhang, M. Graphene quantum dots and their applications in bioimaging, biosensing, and therapy. Adv.
Mater. 2021, 33, 1904362. [CrossRef] [PubMed]
47. Jin, T.; Tiwari, D.K.; Tanaka, S.-i.; Inouye, Y.; Yoshizawa, K.; Watanabe, T.M. Antibody–ProteinA conjugated quantum dots for
multiplexed imaging of surface receptors in living cells. Mol. BioSyst. 2010, 6, 2325–2331. [CrossRef] [PubMed]
48. Tol, J.; Punt, C.J. Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clin. Ther. 2010, 32, 437–453.
[CrossRef]
49. Waldmann, T.A. Monoclonal antibodies in diagnosis and therapy. Science 1991, 252, 1657–1662. [CrossRef] [PubMed]
50. Vogel, C.L.; Cobleigh, M.A.; Tripathy, D.; Gutheil, J.C.; Harris, L.N.; Fehrenbacher, L.; Slamon, D.J.; Murphy, M.; Novotny, W.F.;
Burchmore, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J. Clin. Oncol. 2002, 20, 719–726. [CrossRef] [PubMed]
51. Goldman, E.R.; Balighian, E.D.; Mattoussi, H.; Kuno, M.K.; Mauro, J.M.; Tran, P.T.; Anderson, G.P. Avidin: A natural bridge for
quantum dot-antibody conjugates. J. Am. Chem. Soc. 2002, 124, 6378–6382. [CrossRef] [PubMed]
52. Goldman, E.R.; Anderson, G.P.; Tran, P.T.; Mattoussi, H.; Charles, P.T.; Mauro, J.M. Conjugation of luminescent quantum dots
with antibodies using an engineered adaptor protein to provide new reagents for fluoroimmunoassays. Anal. Chem. 2002, 74,
841–847. [CrossRef] [PubMed]
53. Chang, Y.P.; Pinaud, F.; Antelman, J.; Weiss, S. Tracking bio-molecules in live cells using quantum dots. J. Biophotonics 2008, 1,
287–298. [CrossRef] [PubMed]
54. Iqbal, N.; Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications.
Mol. Biol. Int. 2014, 2014, 852748. [CrossRef] [PubMed]
55. Arkhipov, A.; Shan, Y.; Kim, E.T.; Dror, R.O.; Shaw, D.E. Her2 activation mechanism reflects evolutionary preservation of
asymmetric ectodomain dimers in the human EGFR family. eLife 2013, 2, e00708. [CrossRef] [PubMed]
56. Moasser, M.M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene
2007, 26, 6469. [CrossRef] [PubMed]
57. Nahta, R.; Yuan, L.X.; Zhang, B.; Kobayashi, R.; Esteva, F.J. Insulin-like growth factor-I receptor/human epidermal growth factor
receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65, 11118–11128.
[CrossRef]
58. Karmakar, R. Quantum Dots and it method of preparations-revisited. Prajnan O Sadhona A Sci. Annu. 2015, 2, 116–142.
59. Kucukyildirim, B.O.; Eker, A.A.; Eker, B. Usage of Carbon Nanotubes in Scanning Probe Microscopes as Probe. Int. J. Arts Sci.
2009, 3, 18–26.
60. Tsutsui, K.; Hu, E.L.; Wilkinson, C.D. Reactive ion etched II-VI quantum dots: Dependence of etched profile on pattern geometry.
Jpn. J. Appl. Phys. 1993, 32, 6233. [CrossRef]
61. Bhand, G.R.; Chaure, N.B. Synthesis of CdTe, CdSe and CdTe/CdSe core/shell QDs from wet chemical colloidal method. Mater.
Sci. Semicond. Process. 2017, 68, 279–287. [CrossRef]
62. Qian, H.; Li, L.; Ren, J. One-step and rapid synthesis of high quality alloyed quantum dots (CdSe–CdS) in aqueous phase by
microwave irradiation with controllable temperature. Mater. Res. Bull. 2005, 40, 1726–1736. [CrossRef]
J. Funct. Biomater. 2021, 12, 75 21 of 24
63. Entezari, M.H.; Ghows, N. Micro-emulsion under ultrasound facilitates the fast synthesis of quantum dots of CdS at low
temperature. Ultrason. Sonochem. 2011, 18, 127–134. [CrossRef] [PubMed]
64. O’Connor, É.; O’Riordan, A.; Doyle, H.; Moynihan, S.; Cuddihy, A.; Redmond, G. Near-infrared electroluminescent devices based
on colloidal HgTe quantum dot arrays. Appl. Phys. Lett. 2005, 86, 201114. [CrossRef]
65. Choucair, M.; Thordarson, P.; Stride, J.A. Gram-scale production of graphene based on solvothermal synthesis and sonication.
Nat. Nanotechnol. 2009, 4, 30. [CrossRef]
66. Du, C.-F.; You, T.; Jiang, L.; Yang, S.-Q.; Zou, K.; Han, K.-L.; Deng, W.-Q. Controllable synthesis of ultrasmall CuInSe 2 quantum
dots for photovoltaic application. RSC Adv. 2014, 4, 33855–33860. [CrossRef]
67. Lee, D.U.; Kim, D.H.; Choi, D.H.; Kim, S.W.; Lee, H.S.; Yoo, K.-H.; Kim, T.W. Microstructural and optical properties of
CdSe/CdS/ZnS core-shell-shell quantum dots. Opt. Express 2016, 24, A350–A357. [CrossRef] [PubMed]
68. Whaley, S.R.; English, D.; Hu, E.L.; Barbara, P.F.; Belcher, A.M. Selection of peptides with semiconductor binding specificity for
directed nanocrystal assembly. Nature 2000, 405, 665. [CrossRef] [PubMed]
69. Balandin, A.; Wang, K.; Kouklin, N.; Bandyopadhyay, S. Raman spectroscopy of electrochemically self-assembled CdS quantum
dots. Appl. Phys. Lett. 2000, 76, 137–139. [CrossRef]
70. Bernett, M.J.; Karki, S.; Moore, G.L.; Leung, I.W.; Chen, H.; Pong, E.; Nguyen, D.-H.T.; Jacinto, J.; Zalevsky, J.; Muchhal, U.S.
Engineering fully human monoclonal antibodies from murine variable regions. J. Mol. Biol. 2010, 396, 1474–1490. [CrossRef]
[PubMed]
71. Steinitz, M. Human Monoclonal Antibodies. Methods Mol. Biol. 2014, 111, 22.
72. Medecigo, M.; Manoutcharian, K.; Vasilevko, V.; Govezensky, T.; Munguia, M.; Becerril, B.; Luz-Madrigal, A.; Vaca, L.; Cribbs, D.;
Gevorkian, G. Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody
libraries. J. Neuroimmunol. 2010, 223, 104–114. [CrossRef]
73. Solforosi, L.; Mancini, N.; Canducci, F.; Clementi, N.; Sautto, G.A.; Diotti, R.A.; Clementi, M.; Burioni, R. A phage display vector
optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody
fragments. New Microbiol. 2012, 35, 289–294.
74. Ahmad, Z.A.; Yeap, S.K.; Ali, A.M.; Ho, W.Y.; Alitheen, N.B.M.; Hamid, M. scFv antibody: Principles and clinical application.
Clin. Dev. Immunol. 2012, 2012, 980250. [CrossRef] [PubMed]
75. Mahmuda, A.; Bande, F.; Al-Zihiry, K.J.K.; Abdulhaleem, N.; Majid, R.A.; Hamat, R.A.; Abdullah, W.O.; Unyah, Z. Monoclonal
antibodies: A review of therapeutic applications and future prospects. Trop. J. Pharm. Res. 2017, 16, 713–722. [CrossRef]
76. Carter, P.; Presta, L.; Gorman, C.M.; Ridgway, J.; Henner, D.; Wong, W.; Rowland, A.M.; Kotts, C.; Carver, M.E.; Shepard,
H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 1992, 89, 4285–4289.
[CrossRef] [PubMed]
77. Nahta, R.; Hung, M.-C.; Esteva, F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the
survival of breast cancer cells. Cancer Res. 2004, 64, 2343–2346. [CrossRef] [PubMed]
78. Claret, F.X.; Vu, T.T. Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2012, 2, 62.
79. Hu, X.; Zhang, X.; Jin, W. Applications of electrochemiluminescence resonance energy transfer between CdSe/ZnS quantum dots
and cyanine dye (Cy5) molecules in evaluating interactions and conformational changes of DNA molecules. Electrochim. Acta
2013, 94, 367–373. [CrossRef]
80. Durán, G.M.; Plata, M.R.; Zougagh, M.; Contento, A.M.; Ríos, Á. Microwave-assisted synthesis of water soluble thiol capped
CdSe/ZnS quantum dots and its interaction with sulfonylurea herbicides. J. Colloid. Interface Sci. 2014, 428, 235–241. [CrossRef]
[PubMed]
81. Xing, Y.; Rao, J. Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomark. 2008, 4, 307–319. [PubMed]
82. Hong, Z.-Y.; Lv, C.; Liu, A.-A.; Liu, S.-L.; Sun, E.-Z.; Zhang, Z.-L.; Lei, A.-W.; Pang, D.-W. Clicking hydrazine and aldehyde: The
way to labeling of viruses with quantum dots. ACS Nano 2015, 9, 11750–11760. [CrossRef]
83. Foubert, A.; Beloglazova, N.V.; Rajkovic, A.; Sas, B.; Madder, A.; Goryacheva, I.Y.; De Saeger, S. Bioconjugation of quantum dots:
Review & impact on future application. TrAC Trends Anal. Chem. 2016, 83, 31–48.
84. Hermanson, G.T. Bioconjugate Techniques; Academic Press: Cambridge, MA, USA, 2013.
85. Alivisatos, A.P.; Gu, W.; Larabell, C. Quantum dots as cellular probes. Annu. Rev. Biomed. Eng. 2005, 7, 55–76. [CrossRef]
[PubMed]
86. Pereira, G.; Monteiro, C.A.; Albuquerque, G.M.; Pereira, M.I.; Cabrera, M.P.; Cabral Filho, P.E.; Pereira, G.A.; Fontesa, A.; Santos,
B.S. (Bio) conjugation Strategies Applied to Fluorescent Semiconductor Quantum Dots. J. Braz. Chem. Soc. 2019, 30, 2536–2561.
[CrossRef]
87. Sapsford, K.E.; Pons, T.; Medintz, I.L.; Mattoussi, H. Biosensing with luminescent semiconductor quantum dots. Sensors 2006, 6,
925–953. [CrossRef]
88. Aldeek, F.; Safi, M.; Zhan, N.; Palui, G.; Mattoussi, H. Understanding the self-assembly of proteins onto gold nanoparticles and
quantum dots driven by metal-histidine coordination. ACS Nano 2013, 7, 10197–10210. [CrossRef] [PubMed]
89. Zhan, N.; Palui, G.; Mattoussi, H. Preparation of compact biocompatible quantum dots using multicoordinating molecular-scale
ligands based on a zwitterionic hydrophilic motif and lipoic acid anchors. Nat. Protoc. 2015, 10, 859. [CrossRef] [PubMed]
90. Tsuboi, S.; Sasaki, A.; Sakata, T.; Yasuda, H.; Jin, T. Immunoglobulin binding (B1) domain mediated antibody conjugation to
quantum dots for in vitro and in vivo molecular imaging. Chem. Commun. 2017, 53, 9450–9453. [CrossRef] [PubMed]
J. Funct. Biomater. 2021, 12, 75 22 of 24
91. Tomczak, N.; Liu, R.; Vancso, J.G. Polymer-coated quantum dots. Nanoscale 2013, 5, 12018–12032. [CrossRef]
92. Guo, Y.; Sakonsinsiri, C.; Nehlmeier, I.; Fascione, M.A.; Zhang, H.; Wang, W.; Pöhlmann, S.; Turnbull, W.B.; Zhou, D. Compact,
polyvalent mannose quantum dots as sensitive, ratiometric FRET probes for multivalent protein–ligand interactions. Angew.
Chem. Int. Ed. 2016, 55, 4738–4742. [CrossRef] [PubMed]
93. Diamandis, E.P.; Christopoulos, T.K. The biotin-(strept) avidin system: Principles and applications in biotechnology. Clin. Chem.
1991, 37, 625–636. [CrossRef]
94. Zhang, F.; Lees, E.; Amin, F.; Rivera_Gil, P.; Yang, F.; Mulvaney, P.; Parak, W.J. Polymer-coated nanoparticles: A universal tool for
biolabelling experiments. Small 2011, 7, 3113–3127. [CrossRef] [PubMed]
95. Lesch, H.P.; Kaikkonen, M.U.; Pikkarainen, J.T.; Ylä-Herttuala, S. Avidin-biotin technology in targeted therapy. Expert Opin. Drug
Deliv. 2010, 7, 551–564. [CrossRef] [PubMed]
96. Wang, Z.-y.; Wang, L.-j.; Zhang, Q.; Tang, B.; Zhang, C.-y. Single quantum dot-based nanosensor for sensitive detection of
5-methylcytosine at both CpG and non-CpG sites. Chem. Sci. 2018, 9, 1330–1338. [CrossRef] [PubMed]
97. Hu, J.; Liu, M.-h.; Zhang, C.-y. Integration of isothermal amplification with quantum dot-based fluorescence resonance energy
transfer for simultaneous detection of multiple microRNAs. Chem. Sci. 2018, 9, 4258–4267. [CrossRef] [PubMed]
98. Benoiton, N.L. Chemistry of Peptide Synthesis; CRC Press: Boca Raton, FL, USA, 2016.
99. Ruan, L.; Ge, M.; Huang, X.; Ren, J. Assay of Single-Cell Apoptosis by Ensemble and Single-Molecule Fluorescence Methods:
Annexin-V/Polyethylene Glycol-Functionalized Quantum Dots as Probes. Langmuir 2018, 34, 10040–10047. [CrossRef]
100. Pati, M.L.; Fanizza, E.; Hager, S.; Groza, D.; Heffeter, P.; Laurenza, A.G.; Laquintana, V.; Curri, M.L.; Depalo, N.; Abate, C.
Quantum dot based luminescent nanoprobes for sigma-2 receptor imaging. Mol. Pharm. 2017, 15, 458–471. [CrossRef]
101. Raichlin, S.; Sharon, E.; Freeman, R.; Tzfati, Y.; Willner, I. Electron-transfer quenching of nucleic acid-functionalized CdSe/ZnS
quantum dots by doxorubicin: A versatile system for the optical detection of DNA, aptamer–substrate complexes and telomerase
activity. Biosens. Bioelectron. 2011, 26, 4681–4689. [CrossRef] [PubMed]
102. Wang, J.-H.; Li, Y.-Q.; Zhang, H.-L.; Wang, H.-Q.; Lin, S.; Chen, J.; Zhao, Y.-D.; Luo, Q.-M. Bioconjugation of concanavalin and
CdTe quantum dots and the detection of glucose. Colloids Surf. A: Physicochem. Eng. Asp. 2010, 364, 82–86. [CrossRef]
103. Chen, Z.; Lu, M. Novel electrochemical immunoassay for human IgG1 using metal sulfide quantum dot-doped bovine serum
albumin microspheres on antibody-functionalized magnetic beads. Anal. Chim. Acta 2017, 979, 24–30. [CrossRef] [PubMed]
104. Gao, J.; Chen, K.; Miao, Z.; Ren, G.; Chen, X.; Gambhir, S.S.; Cheng, Z. Affibody-based nanoprobes for HER2-expressing cell and
tumor imaging. Biomaterials 2011, 32, 2141–2148. [CrossRef] [PubMed]
105. Vazquez, A.Q.; Torchynska, T.; Espinola, J.C.; Gómez, J.J.; Douda, J. Electronic effects in emission of core/shell CdSe/ZnS
quantum dots conjugated to anti-Interleukin 10 antibodies. J. Lumin. 2013, 143, 38–42. [CrossRef]
106. Kobirumaki, F.; Yumoto, M.; Watanabe, M. Real-time tracking of single quantum dots conjugated with monoclonal anti-smooth
muscle myosin antibody in intact and skinned taenia caeci from guinea pig. In Proceedings of the Proceedings of Annual Meeting
of the Physiological Society of Japan, Tokyo, Japan, 25–27 March 2008; p. 66.
107. Jaiswal, J.K.; Mattoussi, H.; Mauro, J.M.; Simon, S.M. Long-term multiple color imaging of live cells using quantum dot
bioconjugates. Nat. Biotechnol. 2003, 21, 47. [CrossRef]
108. Medintz, I.L.; Uyeda, H.T.; Goldman, E.R.; Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat.
Mater. 2005, 4, 435. [CrossRef] [PubMed]
109. Chen, F.; Gerion, D. Fluorescent CdSe/ZnS nanocrystal− peptide conjugates for long-term, nontoxic imaging and nuclear
targeting in living cells. Nano Lett. 2004, 4, 1827–1832. [CrossRef]
110. Han, S.-J.; Rathinaraj, P.; Park, S.-Y.; Kim, Y.K.; Lee, J.H.; Kang, I.-K.; Moon, J.-S.; Winiarz, J.G. Specific intracellular uptake of
herceptin-conjugated CdSe/ZnS quantum dots into breast cancer cells. BioMed Res. Int. 2014, 2014, 954307. [CrossRef] [PubMed]
111. Tada, H.; Higuchi, H.; Wanatabe, T.M.; Ohuchi, N. In vivo real-time tracking of single quantum dots conjugated with monoclonal
anti-HER2 antibody in tumors of mice. Cancer Res. 2007, 67, 1138–1144. [CrossRef] [PubMed]
112. Nurunnabi, M.; Cho, K.J.; Choi, J.S.; Huh, K.M.; Lee, Y.-k. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging.
Biomaterials 2010, 31, 5436–5444. [CrossRef] [PubMed]
113. Núñez, C.; Estévez, S.V.; del Pilar Chantada, M. Inorganic nanoparticles in diagnosis and treatment of breast cancer. JBIC J. Biol.
Inorg. Chem. 2018, 23, 331–345. [CrossRef] [PubMed]
114. Yue, D.; Wang, M.; Deng, F.; Yin, W.; Zhao, H.; Zhao, X.; Xu, Z. Biomarker-targeted fluorescent probes for breast cancer imaging.
Chin. Chem. Lett. 2018, 29, 648–656. [CrossRef]
115. Colombo, M.; Corsi, F.; Foschi, D.; Mazzantini, E.; Mazzucchelli, S.; Morasso, C.; Occhipinti, E.; Polito, L.; Prosperi, D.; Ronchi, S.
HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical
approaches. Pharmacol. Res. 2010, 62, 150–165. [CrossRef] [PubMed]
116. Luo, G.; Long, J.; Zhang, B.; Liu, C.; Ji, S.; Xu, J.; Yu, X.; Ni, Q. Quantum dots in cancer therapy. Expert Opin. Drug Deliv. 2012, 9,
47–58. [CrossRef] [PubMed]
117. Gu, Y.; Kuskovsky, I.L.; Fung, J.; Robinson, R.; Herman, I.; Neumark, G.; Zhou, X.; Guo, S.; Tamargo, M. Determination of size
and composition of optically active CdZnSe/ZnBeSe quantum dots. Appl. Phys. Lett. 2003, 83, 3779–3781. [CrossRef]
118. Rameshwar, T.; Samal, S.; Lee, S.; Kim, S.; Cho, J.; Kim, I.S. Determination of the size of water-soluble nanoparticles and quantum
dots by field-flow fractionation. J. Nanosci. Nanotechnol. 2006, 6, 2461–2467. [CrossRef] [PubMed]
J. Funct. Biomater. 2021, 12, 75 23 of 24
119. Hapke-Wurst, I.; Zeitler, U.; Schumacher, H.; Haug, R.; Pierz, K.; Ahlers, F. Size determination of InAs quantum dots using
magneto-tunnelling experiments. Semicond. Sci. Technol. 1999, 14, L41. [CrossRef]
120. Yamauchi, T.; Matsuba, Y.; Ohyama, Y.; Tabuchi, M.; Nakamura, A.; Akahane, K.; Lan, S.; Kawamura, T.; Takamasu, T.; Kido, G.
Quantum Size Effects of InAs-and InGaAs-Quantum Dots Studied by Scanning Tunneling Microscopy/Spectroscopy. Appl. Phys.
Lett. 1997, 71, 1083. [CrossRef]
121. Drbohlavova, J.; Adam, V.; Kizek, R.; Hubalek, J. Quantum dots—characterization, preparation and usage in biological systems.
Int. J. Mol. Sci. 2009, 10, 656–673. [CrossRef] [PubMed]
122. Lee, J.-O.; So, H.-M.; Jeon, E.-K.; Chang, H.; Won, K.; Kim, Y.H. Aptamers as molecular recognition elements for electrical
nanobiosensors. Anal. Bioanal. Chem. 2008, 390, 1023–1032. [CrossRef]
123. Zhang, P.; Lu, H.; Chen, J.; Han, H.; Ma, W. Simple and sensitive detection of HBsAg by using a quantum dots nanobeads based
dot-blot immunoassay. Theranostics 2014, 4, 307. [CrossRef] [PubMed]
124. Zhao, Y.; Zhang, Q.; Meng, Q.; Wu, F.; Zhang, L.; Tang, Y.; Guan, Y.; An, L. Quantum dots-based lateral flow immunoassay
combined with image analysis for semiquantitative detection of IgE antibody to mite. Int. J. Nanomed. 2017, 12, 4805. [CrossRef]
[PubMed]
125. Vo, N.; Ngo, H.; Vu, D.; Duong, A.; Lam, Q. Conjugation of E. coli O157: H7 antibody to CdSe/ZnS quantum dots. J. Nanomater.
2015, 2015, 8. [CrossRef]
126. Kotagiri, N.; Li, Z.; Xu, X.; Mondal, S.; Nehorai, A.; Achilefu, S. Antibody quantum dot conjugates developed via copper-free
click chemistry for rapid analysis of biological samples using a microfluidic microsphere array system. Bioconjugate Chem. 2014,
25, 1272–1281. [CrossRef]
127. Ahmad, S.A.A.; Zaini, M.S.; Kamarudin, M.A. An Electrochemical Sandwich Immunosensor for the Detection of HER2 using
Antibody-Conjugated PbS Quantum Dot as a label. J. Pharm. Biomed. Anal. 2019, 174, 608–617.
128. Rizvi, S.B.; Rouhi, S.; Taniguchi, S.; Yang, S.Y.; Green, M.; Keshtgar, M.; Seifalian, A.M. Near-infrared quantum dots for HER2
localization and imaging of cancer cells. Int. J. Nanomed. 2014, 9, 1323.
129. Pinaud, F.; King, D.; Moore, H.-P.; Weiss, S. Bioactivation and cell targeting of semiconductor CdSe/ZnS nanocrystals with
phytochelatin-related peptides. J. Am. Chem. Soc. 2004, 126, 6115–6123. [CrossRef] [PubMed]
130. Gerion, D.; Pinaud, F.; Williams, S.C.; Parak, W.J.; Zanchet, D.; Weiss, S.; Alivisatos, A.P. Synthesis and properties of biocompatible
water-soluble silica-coated CdSe/ZnS semiconductor quantum dots. J. Phys. Chem. B 2001, 105, 8861–8871. [CrossRef]
131. Parce, J.W.; Nikiforov, T.T.; Mehta, T.B.; Kopf-Sill, A.R.; Chow, A.W.; Knapp, M.R. Sequencing by Incorporation. U.S. Patent
6613513B1, 2 September 2003.
132. Nehilla, B.J.; Vu, T.Q.; Desai, T.A. Stoichiometry-Dependent Formation of Quantum Dot− Antibody Bioconjugates: A Comple-
mentary Atomic Force Microscopy and Agarose Gel Electrophoresis Study. J. Phys. Chem. B 2005, 109, 20724–20730. [CrossRef]
[PubMed]
133. Rakovich, T.Y.; Mahfoud, O.K.; Mohamed, B.M.; Prina-Mello, A.; Crosbie-Staunton, K.; Van Den Broeck, T.; De Kimpe, L.;
Sukhanova, A.; Baty, D.; Rakovich, A. Highly sensitive single domain antibody–quantum dot conjugates for detection of HER2
biomarker in lung and breast cancer cells. ACS Nano 2014, 8, 5682–5695. [CrossRef]
134. Kairdolf, B.A.; Smith, A.M.; Stokes, T.H.; Wang, M.D.; Young, A.N.; Nie, S. Semiconductor quantum dots for bioimaging and
biodiagnostic applications. Annu. Rev. Anal. Chem. 2013, 6, 143–162. [CrossRef]
135. Azzazy, H.M.; Mansour, M.M.; Kazmierczak, S.C. From diagnostics to therapy: Prospects of quantum dots. Clin. Biochem. 2007,
40, 917–927. [CrossRef]
136. Schroeder, J.; Shweky, I.; Shmeeda, H.; Banin, U.; Gabizon, A. Folate-mediated tumor cell uptake of quantum dots entrapped in
lipid nanoparticles. J. Control. Release 2007, 124, 28–34. [CrossRef] [PubMed]
137. Walling, M.A.; Novak, J.A.; Shepard, J.R. Quantum dots for live cell and in vivo imaging. Int. J. Mol. Sci. 2009, 10, 441–491.
[CrossRef] [PubMed]
138. Maysinger, D.; Behrendt, M.; Lalancette-Hébert, M.; Kriz, J. Real-time imaging of astrocyte response to quantum dots: In vivo
screening model system for biocompatibility of nanoparticles. Nano Lett. 2007, 7, 2513–2520. [CrossRef] [PubMed]
139. Bakalova, R.; Zhelev, Z.; Aoki, I.; Masamoto, K.; Mileva, M.; Obata, T.; Higuchi, M.; Gadjeva, V.; Kanno, I. Multimodal silica-
shelled quantum dots: Direct intracellular delivery, photosensitization, toxic, and microcirculation effects. Bioconjugate Chem.
2008, 19, 1135–1142. [CrossRef]
140. Chang, J.-C.; Su, H.-L.; Hsu, S.-h. The use of peptide-delivery to protect human adipose-derived adult stem cells from damage
caused by the internalization of quantum dots. Biomaterials 2008, 29, 925–936. [CrossRef]
141. Hoshino, A.; Hanaki, K.-I.; Suzuki, K.; Yamamoto, K. Applications of T-lymphoma labeled with fluorescent quantum dots to cell
tracing markers in mouse body. Biochem. Biophys. Res. Commun. 2004, 314, 46–53. [CrossRef]
142. Beer, A.J.; Schwaiger, M. Imaging of integrin αvβ3 expression. Cancer Metastasis Rev. 2008, 27, 631–644. [CrossRef]
143. Molaei, M.J. Carbon quantum dots and their biomedical and therapeutic applications: A review. RSC Adv. 2019, 9, 6460–6481.
[CrossRef]
144. Bhuckory, S.; Mattera, L.; Wegner, K.; Qiu, X.; Wu, Y.-T.; Charbonniere, L.; Reiss, P.; Hildebrandt, N. Direct conjugation of
antibodies to the ZnS shell of quantum dots for FRET immunoassays with low picomolar detection limits. Chem. Commun. 2016,
52, 14423–14425. [CrossRef]
J. Funct. Biomater. 2021, 12, 75 24 of 24
145. Chakraborty, I.; Pradeep, T. Atomically precise clusters of noble metals: Emerging link between atoms and nanoparticles. Chem.
Rev. 2017, 117, 8208–8271. [CrossRef] [PubMed]
146. Ghazani, A.A.; Lee, J.A.; Klostranec, J.; Xiang, Q.; Dacosta, R.S.; Wilson, B.C.; Tsao, M.S.; Chan, W.C. High throughput
quantification of protein expression of cancer antigens in tissue microarray using quantum dot nanocrystals. Nano Lett. 2006, 6,
2881–2886. [CrossRef]
147. Chen, J.; Pan, J.; Zhao, J.; Qiu, X.; Zheng, J.; Wang, Z.; Huang, Y.; Chu, H. Quantum dot imaging for HSP70 and HSF-1 kinetics in
SCC-25 cells with or without leucine deprivation following heat shock. Oncol. Rep. 2013, 29, 2255–2260. [CrossRef] [PubMed]
148. Sun, J.-Z.; Chen, C.; Jiang, G.; Tian, W.-Q.; Li, Y.; Sun, S.-R. Quantum dot-based immunofluorescent imaging of Ki67 and
identification of prognostic value in HER2-positive (non-luminal) breast cancer. Int. J. Nanomed. 2014, 9, 1339. [CrossRef]
[PubMed]
149. Lee, J.J.; Yazan, L.S.; Abdullah, C.A.C. A review on current nanomaterials and their drug conjugate for targeted breast cancer
treatment. Int. J. Nanomed. 2017, 12, 2373. [CrossRef] [PubMed]
150. Kievit, F.M.; Zhang, M. Cancer nanotheranostics: Improving imaging and therapy by targeted delivery across biological barriers.
Adv. Mater. 2011, 23, H217–H247. [CrossRef]
